NASDAQ:FPRX - Five Prime Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $16.97 -0.19 (-1.11 %) (As of 07/22/2018 12:36 PM ET)Previous Close$16.97Today's Range$16.85 - $17.1852-Week Range$15.32 - $48.87Volume111,405 shsAverage Volume271,575 shsMarket Capitalization$597.50 millionP/E Ratio-3.15Dividend YieldN/ABeta3.42 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor. Its product candidates also comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor IIb, which is in Phase I clinical trials to treat patients with gastric or gastroesophageal junction and bladder cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 as a monotherapy in various cancers. The company's FP-1039 is in Phase Ib clinical trials to treat patients with malignant pleural mesothelioma. Its preclinical product candidates include FPA150, a CD8 T cell checkpoint inhibitor antibody; FPA154, a tetravalent agonistic antibody that activates glucocorticoid-induced tumor necrosis factor receptor; and FPT155, a CD80-Fc fusion protein, which modulates signaling pathways. The company has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with bluebird bio, Inc., Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. Five Prime Therapeutics, Inc. was founded in 2001 and is headquartered in South San Francisco, California. Receive FPRX News and Ratings via Email Sign-up to receive the latest news and ratings for FPRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:FPRX CUSIPN/A Webwww.fiveprime.com Phone415-365-5600 Debt Debt-to-Equity RatioN/A Current Ratio9.79 Quick Ratio9.79 Price-To-Earnings Trailing P/E Ratio-3.15 Forward P/E Ratio-3.63 P/E GrowthN/A Sales & Book Value Annual Sales$39.51 million Price / Sales15.12 Cash FlowN/A Price / CashN/A Book Value$7.80 per share Price / Book2.18 Profitability EPS (Most Recent Fiscal Year)($5.38) Net Income$-150,220,000.00 Net Margins-221.74% Return on Equity-44.36% Return on Assets-36.14% Miscellaneous Employees216 Outstanding Shares35,210,000Market Cap$597.50 Five Prime Therapeutics (NASDAQ:FPRX) Frequently Asked Questions What is Five Prime Therapeutics' stock symbol? Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX." How were Five Prime Therapeutics' earnings last quarter? Five Prime Therapeutics Inc (NASDAQ:FPRX) released its earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by $0.08. The biotechnology company earned $32.49 million during the quarter, compared to analyst estimates of $37.50 million. Five Prime Therapeutics had a negative return on equity of 44.36% and a negative net margin of 221.74%. View Five Prime Therapeutics' Earnings History. What price target have analysts set for FPRX? 8 brokerages have issued twelve-month price targets for Five Prime Therapeutics' shares. Their predictions range from $17.00 to $60.00. On average, they anticipate Five Prime Therapeutics' stock price to reach $34.7143 in the next year. This suggests a possible upside of 104.6% from the stock's current price. View Analyst Ratings for Five Prime Therapeutics. What is the consensus analysts' recommendation for Five Prime Therapeutics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Five Prime Therapeutics in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of Five Prime Therapeutics' key competitors? Some companies that are related to Five Prime Therapeutics include Enanta Pharmaceuticals (ENTA), Xencor (XNCR), Akorn (AKRX), Arena Pharmaceuticals (ARNA), TESARO (TSRO), Global Blood Therapeutics (GBT), ACADIA Pharmaceuticals (ACAD), Zogenix (ZGNX), Myokardia (MYOK), Puma Biotechnology (PBYI), Phibro Animal Health (PAHC), Insmed (INSM), Prestige Brands (PBH), PTC Therapeutics (PTCT) and Cambrex (CBM). Who are Five Prime Therapeutics' key executives? Five Prime Therapeutics' management team includes the folowing people: Dr. Lewis T. Williams, Founder & Exec. Chairman (Age 69)Mr. Aron Marc Knickerbocker, Pres, CEO & Director (Age 49)Dr. Kevin P. Baker, Sr. VP of Devel. Sciences (Age 57)Dr. Peder K. Jensen, Advisor & Director (Age 63)Mr. Jeff P. Coon, Sr. VP of HR (Age 55) Has Five Prime Therapeutics been receiving favorable news coverage? Media stories about FPRX stock have trended very positive recently, according to Accern. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Five Prime Therapeutics earned a media sentiment score of 0.51 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 48.24 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days. Who are Five Prime Therapeutics' major shareholders? Five Prime Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Fox Run Management L.L.C. (0.07%). Company insiders that own Five Prime Therapeutics stock include Francis Willard Sarena, Lewis T Williams, Peder Jensen and William R Ringo. View Institutional Ownership Trends for Five Prime Therapeutics. Which institutional investors are buying Five Prime Therapeutics stock? FPRX stock was purchased by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C.. View Insider Buying and Selling for Five Prime Therapeutics. How do I buy shares of Five Prime Therapeutics? Shares of FPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Five Prime Therapeutics' stock price today? One share of FPRX stock can currently be purchased for approximately $16.97. How big of a company is Five Prime Therapeutics? Five Prime Therapeutics has a market capitalization of $597.50 million and generates $39.51 million in revenue each year. The biotechnology company earns $-150,220,000.00 in net income (profit) each year or ($5.38) on an earnings per share basis. Five Prime Therapeutics employs 216 workers across the globe. How can I contact Five Prime Therapeutics? Five Prime Therapeutics' mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 415-365-5600. MarketBeat Community Rating for Five Prime Therapeutics (NASDAQ FPRX)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 233 (Vote Outperform)Underperform Votes: 156 (Vote Underperform)Total Votes: 389MarketBeat's community ratings are surveys of what our community members think about Five Prime Therapeutics and other stocks. Vote "Outperform" if you believe FPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FPRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/22/2018 by MarketBeat.com StaffFeatured Article: What does RSI mean?